Journal of Blood Medicine最新文献

筛选
英文 中文
Prevalence of Reactive Screening Markers for HIV, Hepatitis B, Hepatitis C, and Syphilis Among Blood Donors at the Provincial Hospital of Sarh, Chad: A Retrospective Cross-Sectional Study. 乍得萨拉省医院献血者中HIV、乙肝、丙肝和梅毒反应性筛查标志物的流行:一项回顾性横断面研究
IF 2.1
Journal of Blood Medicine Pub Date : 2026-11-04 eCollection Date: 2026-01-01 DOI: 10.2147/JBM.S649330
Ali Barka Mahamat, Mahamat Hassan Abdel-Aziz, Abdoulaye Brahim Bechir, Bayangbe Emmanuel Djakmoudwé, Hamit Mahamat Alio
{"title":"Prevalence of Reactive Screening Markers for HIV, Hepatitis B, Hepatitis C, and Syphilis Among Blood Donors at the Provincial Hospital of Sarh, Chad: A Retrospective Cross-Sectional Study.","authors":"Ali Barka Mahamat, Mahamat Hassan Abdel-Aziz, Abdoulaye Brahim Bechir, Bayangbe Emmanuel Djakmoudwé, Hamit Mahamat Alio","doi":"10.2147/JBM.S649330","DOIUrl":"https://doi.org/10.2147/JBM.S649330","url":null,"abstract":"<p><strong>Introduction: </strong>Blood transfusion safety remains a challenge in resource-limited settings. This study estimated the prevalence of reactive screening markers for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis among blood donors at Sarh Provincial Hospital, Chad.</p><p><strong>Methods: </strong>This retrospective cross-sectional study used blood bank register data from 18 September to 18 November 2023. Of 2,868 records identified, 27 were excluded and 2,841 donors were analyzed. Screening used rapid diagnostic tests; confirmatory testing was unavailable. Prevalence estimates and 95% confidence intervals (CIs) were calculated.</p><p><strong>Results: </strong>Participants included 2,173 men (76.49%) and 668 women (23.51%); 97.75% were family/replacement donors. Reactive markers were HBV 275/2,841 (9.68%; 95% CI 8.64-10.83), syphilis 177/2,841 (6.23%; 95% CI 5.39-7.18), HCV 104/2,841 (3.66%; 95% CI 3.03-4.42), and HIV 95/2,841 (3.34%; 95% CI 2.74-4.07). Overall, 584 donors (20.56%) had at least one reactive marker, and 64 (2.25%) had multiple-marker reactivity. No significant sex differences were observed; age trends were not significant for HBV or HCV.</p><p><strong>Conclusion: </strong>HBV and syphilis were the most frequent reactive screening markers. Because confirmatory testing was not available, results represent screening-marker reactivity rather than laboratory-confirmed infection. Findings are limited to this hospital and the two-month study period. Strengthening voluntary non-remunerated donation, quality assurance, confirmatory testing, and surveillance may improve blood safety.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"17 ","pages":"649330"},"PeriodicalIF":2.1,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13744704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population-Impact Model Estimating Clinical and Economic Outcomes Associated with Emicizumab in People with Moderate or Severe Hemophilia a in the US. 美国中重度血友病a患者使用Emicizumab相关的临床和经济结果的人群影响模型
IF 2.1
Journal of Blood Medicine Pub Date : 2026-11-04 eCollection Date: 2026-01-01 DOI: 10.2147/JBM.S619045
Janet S Lee, Fadoua El Moustaid, Lucy Y Lee
{"title":"Population-Impact Model Estimating Clinical and Economic Outcomes Associated with Emicizumab in People with Moderate or Severe Hemophilia a in the US.","authors":"Janet S Lee, Fadoua El Moustaid, Lucy Y Lee","doi":"10.2147/JBM.S619045","DOIUrl":"https://doi.org/10.2147/JBM.S619045","url":null,"abstract":"<p><strong>Background: </strong>Emicizumab, a recombinant, humanized, bispecific, monoclonal antibody, has become the standard of prophylactic care for people with hemophilia A since its US approval in 2017. The objective was to estimate the population-level impact of emicizumab on clinical and economic outcomes since its approval and to project the impact over the next 10 years.</p><p><strong>Methods: </strong>A population impact model estimated outcomes associated with emicizumab market approval and uptake compared with a hypothetical scenario in which emicizumab is unavailable. The model evaluated people with moderate or severe hemophilia A (with or without inhibitors) during two time periods: 2016 to 2025 and 2026 to 2035. Outcomes included the number of treated bleeds averted (including treated joint bleeds), the number of arthroplasties prevented, and the total estimated direct healthcare costs and indirect productivity costs associated with these avoided outcomes. Market share values were assumed to remain constant, with no additional therapies entering the market over the next ten years (2026-2035), when evaluating outcomes for both scenarios.</p><p><strong>Results: </strong>Among an estimated 15,107 people in the US with moderate or severe hemophilia A in 2016, use of emicizumab has resulted in an estimated cumulative total of 958,810 treated bleeds averted (including 699,931 treated joint bleeds) and 2002 arthroplasties prevented since its approval. These avoided outcomes were associated with an estimated $42.6B in direct and indirect costs to payers. Over the next ten years, emicizumab treatment was projected to result in an additional 1.9M treated bleeds averted (including 1.4M treated joint bleeds) and 3292 arthroplasties prevented, with an estimated $80.5B in associated costs.</p><p><strong>Conclusion: </strong>In this US population impact model, emicizumab significantly reduced both bleeding events and the economic burden of hemophilia A.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"17 ","pages":"619045"},"PeriodicalIF":2.1,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13744712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Life Expectancy in Hairy Cell Leukemia: An Updated SEER Study of 5669 Patients. 毛细胞白血病的预期寿命:5669例患者的最新SEER研究
IF 2.1
Journal of Blood Medicine Pub Date : 2026-11-03 eCollection Date: 2026-01-01 DOI: 10.2147/JBM.S637330
Alamin Mustafa
{"title":"Life Expectancy in Hairy Cell Leukemia: An Updated SEER Study of 5669 Patients.","authors":"Alamin Mustafa","doi":"10.2147/JBM.S637330","DOIUrl":"10.2147/JBM.S637330","url":null,"abstract":"<p><strong>Introduction: </strong>Hairy cell leukemia (HCL) is a rare lymphoproliferative disorder affecting mature B-cells, predominantly observed in males. It is recognized by cytopenia, splenomegaly, myelofibrosis, and the presence of atypical lymphoid cells exhibiting distinctive cytoplasmic hairy projections.</p><p><strong>Methods: </strong>This large updated population-based study utilized SEER database to evaluate 5669 hairy cell leukemia (HCL) patients diagnosed between 1978 and 2020. Univariate and multivariate Cox proportional hazards models were performed to identify key determinants of overall survival (OS). While the SEER database provides robust statistical power and broad generalizability, this analysis is inherently limited by registry-level constraints, including missing treatment details (such as specific chemotherapy regimens or lines of therapy), lack of relapse/progression data, and potential underreporting of comorbidities.</p><p><strong>Results: </strong>Estimated median survival for HCL patients who aged less than 40 years was 39.3 (95% CI: 38.9-39.7 years) compared to 8.8 years (95% CI: 8.0-9.4 years) for HCL patients older than 65 years.</p><p><strong>Conclusion: </strong>This study demonstrates favorable long-term survival among patients with HCL. Improved OS is associated with more recent diagnosis (post-2006) and the use of advanced diagnostic methods. These findings suggest that long-term survival in HCL may approach that of the general population, though these findings reflect cohort-level observations without a matched population control.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"17 ","pages":"637330"},"PeriodicalIF":2.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13744203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iron Depletion in Repeat Male Plateletpheresis Donors: Prevalence and Associated Factors in a Cross-Sectional Study. 重复男性血小板献血者的铁缺乏:横断面研究中的患病率和相关因素。
IF 2.1
Journal of Blood Medicine Pub Date : 2026-11-01 eCollection Date: 2026-01-01 DOI: 10.2147/JBM.S646810
Thidawan Maikula, Piangrawee Niprapan, Maitree Sriwichai, Sirichai Srichairatanakool, Teerachat Punnachet, Nonthakorn Hantrakun, Pokpong Piriyakhuntorn, Thanawat Rattanathammethee, Ekarat Rattarittamrong, Sasinee Hantrakool
{"title":"Iron Depletion in Repeat Male Plateletpheresis Donors: Prevalence and Associated Factors in a Cross-Sectional Study.","authors":"Thidawan Maikula, Piangrawee Niprapan, Maitree Sriwichai, Sirichai Srichairatanakool, Teerachat Punnachet, Nonthakorn Hantrakun, Pokpong Piriyakhuntorn, Thanawat Rattanathammethee, Ekarat Rattarittamrong, Sasinee Hantrakool","doi":"10.2147/JBM.S646810","DOIUrl":"10.2147/JBM.S646810","url":null,"abstract":"<p><strong>Purpose: </strong>Iron depletion is increasingly recognized among repeat plateletpheresis donors despite the return of red blood cells during apheresis. However, data on iron status and factors associated with reduced iron stores in plateletpheresis donors in Thailand remain limited. This study aimed to determine the prevalence of iron depletion and identify factors associated with lower iron stores among repeat plateletpheresis donors.</p><p><strong>Patients and methods: </strong>This cross-sectional study included healthy, non-anemic male repeat plateletpheresis donors at a university hospital blood bank in Thailand. Donors were categorized into three groups according to serum ferritin levels: iron depletion (≤30 µg/L), intermediate iron stores (31-100 µg/L), and higher iron stores (>100 µg/L). Demographic characteristics, donation history, hematologic parameters, and iron indices were evaluated. Factors associated with iron depletion were explored using univariable logistic regression, whereas factors associated with ferritin ≤100 µg/L were evaluated using univariable and multivariable logistic regression.</p><p><strong>Results: </strong>Among 150 participants, iron depletion was identified in 6 donors (4.0%; 95% CI, 1.5-8.5%), 42 had intermediate iron stores (28.0%; 95% CI, 21.0-35.9%), and 102 donors had ferritin >100 µg/L (68.0%; 95% CI, 59.9-75.4%). Platelet donation frequency, platelet donation volume during the preceding year, lifetime platelet donations, and recent whole blood donation were not significantly associated with either ferritin threshold. In multivariable analysis, body weight (adjusted OR, 0.963; 95% CI, 0.929-0.998; p=0.036) and reticulocyte count (OR, 0.205; 95% CI, 0.066-0.637; p=0.006) were independently associated with ferritin ≤100 µg/L.</p><p><strong>Conclusion: </strong>Iron depletion was uncommon, but one-third of non-anemic repeat plateletpheresis donors had ferritin ≤100 µg/L. Lower body weight and lower reticulocyte count were associated with this ferritin threshold in exploratory analyses. Prospective studies are required to confirm these findings before targeted iron-status screening strategies can be recommended.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"17 ","pages":"646810"},"PeriodicalIF":2.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13738225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge and Practices Towards Premarital Sickle Cell Trait Testing Among Young Adults in Eastern Uganda. 乌干达东部年轻人婚前镰状细胞特征检测的知识和实践。
IF 2.1
Journal of Blood Medicine Pub Date : 2026-10-25 eCollection Date: 2026-01-01 DOI: 10.2147/JBM.S643667
Precious Thereza Namazzi, Abudu Rahuman Ssekabira, Ethel Turyasingura Snr, Jacintah Nyesigye, Edsone Ssemujju, Emmanuel Ikaara, Gladys Nakidde
{"title":"Knowledge and Practices Towards Premarital Sickle Cell Trait Testing Among Young Adults in Eastern Uganda.","authors":"Precious Thereza Namazzi, Abudu Rahuman Ssekabira, Ethel Turyasingura Snr, Jacintah Nyesigye, Edsone Ssemujju, Emmanuel Ikaara, Gladys Nakidde","doi":"10.2147/JBM.S643667","DOIUrl":"https://doi.org/10.2147/JBM.S643667","url":null,"abstract":"<p><strong>Background: </strong>Sickle cell disease (SCD) is a major global health challenge, with over 75% of the burden concentrated in sub-Saharan Africa. Premarital sickle cell trait testing (SCTT) enables informed reproductive decisions that can help carriers reduce the risk of having children with SCD, yet uptake remains poorly documented among young adults in the region.</p><p><strong>Objective: </strong>To assess knowledge and practices towards premarital SCTT among young adults aged 18-35 years attending the outpatient department (OPD) of a regional referral hospital in Eastern Uganda.</p><p><strong>Methods: </strong>A descriptive cross-sectional study was conducted among 298 young adults attending the OPD at Soroti Regional Referral Hospital (SRRH), selected using simple random sampling. Data were collected via pretested, self-administered questionnaires and analyzed in SPSS version 27 using descriptive statistics and exploratory subgroup comparisons.</p><p><strong>Results: </strong>Of 298 participants, 64.1% were female, with a median age of 28 years (range 18-35). Awareness of SCD was high (95.3%); 93.0% knew it is inherited and 78.2% knew it is incurable. Most (79.2%) had heard of SCTT, mainly through hospitals (63.6%) and radio (36.9%), but only 12.1% had ever been tested, and 61.1% did not know premarital testing could inform couples of their risk of having a child with SCD. Half (50.0%) had avoided SCTT, citing lack of access (59.1%) and fear of positive results (31.5%) as leading reasons; positive SCTT practice remained low across subgroups, slightly higher among those fearing relationship termination (1.3%).</p><p><strong>Conclusion: </strong>Young adults attending OPD at SRRH showed moderate awareness of SCTT but low uptake. Although most understood that SCD is inherited and incurable, many lacked knowledge of the risk-informing role of premarital testing. Barriers including limited access, fear of positive results, and relationship concerns contributed to low uptake, revealing a knowledge-practice gap that calls for targeted interventions in Eastern Uganda.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"17 ","pages":"643667"},"PeriodicalIF":2.1,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13718321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149297987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence, Predictors, and Management of Acute Chest Syndrome in Patients with Sickle Cell Disease at Muhimbili National Hospital, Tanzania: A Retrospective Study. 坦桑尼亚Muhimbili国家医院镰状细胞病患者急性胸综合征的患病率、预测因素和管理:一项回顾性研究。
IF 2.1
Journal of Blood Medicine Pub Date : 2026-10-23 eCollection Date: 2026-01-01 DOI: 10.2147/JBM.S603553
Safia A Masoud, Mwashungi Ally, Helena Tom Kakumbula, Ahlam Nasser, Clara Chamba, Magdalena Lyimo, William Mawalla, Agnes Jonathan, Ritah Mutagonda, Florence Urio, Johnson Mshiu, Hilda Tutuba, Irene Kida Minja, Avelina Mgasa, Tunganege Edward Matipa, Julie Makani, Emmanuel Balandya
{"title":"Prevalence, Predictors, and Management of Acute Chest Syndrome in Patients with Sickle Cell Disease at Muhimbili National Hospital, Tanzania: A Retrospective Study.","authors":"Safia A Masoud, Mwashungi Ally, Helena Tom Kakumbula, Ahlam Nasser, Clara Chamba, Magdalena Lyimo, William Mawalla, Agnes Jonathan, Ritah Mutagonda, Florence Urio, Johnson Mshiu, Hilda Tutuba, Irene Kida Minja, Avelina Mgasa, Tunganege Edward Matipa, Julie Makani, Emmanuel Balandya","doi":"10.2147/JBM.S603553","DOIUrl":"https://doi.org/10.2147/JBM.S603553","url":null,"abstract":"<p><strong>Background: </strong>Acute Chest Syndrome (ACS) is a potentially life-threatening complication of Sickle Cell Disease (SCD), contributing significantly to hospitalizations and mortality. While extensively studied in high-income settings, there is limited data on its prevalence, associated factors, and treatment patterns in Tanzania.</p><p><strong>Objective: </strong>To determine the prevalence, predictors, and management of ACS among SCD patients admitted at Muhimbili National Hospital (MNH), Dar es Salaam, between January 2019 and December 2024.</p><p><strong>Methods: </strong>A retrospective study was conducted using medical records of 1,257 SCD patients admitted to MNH. Data on demographics, clinical and laboratory characteristics, and treatment interventions were extracted and analyzed. Modified Poisson regression was used to identify factors associated with ACS.</p><p><strong>Results: </strong>The prevalence of ACS was 24.3%. ACS was more likely among children under the age of five years compared to adults above 17 years (adjusted prevalence ratio [aPR] = 2.04, 95% CI: 1.76-2.38), in patients with upper respiratory tract infections (aPR = 1.62, 95% CI: 1.47-1.79) and in those with vaso-occlusive crises (aPR = 2.24, 95% CI: 2.12-2.38), while the use of hydroxyurea (aPR = 0.78, 95% CI: 0.78-0.79) and a history of asthma (aPR = 0.37, 95% CI: 0.27-0.47) were associated with a lower prevalence of ACS. Treatment offered included antibiotics (94.4%), pain management (87.2%), intravenous hydration (76.7%), oxygen therapy (43.9%), simple top-up blood transfusion (42.0%) and mechanical ventilation (9.8%). Exchange transfusion was underutilized (0.7%).</p><p><strong>Conclusion: </strong>ACS remains a common complication among patients with SCD admitted to MNH, particularly among younger patients and those presenting with upper respiratory tract infections or vaso-occlusive crises. Hydroxyurea use and a history of asthma were associated with a lower prevalence of ACS in this cohort. Exchange transfusion was the least utilized treatment modality despite current recommendations. These findings highlight the need to strengthen preventive strategies, improve access to hydroxyurea, and address barriers to advanced ACS management, including exchange transfusion.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"17 ","pages":"603553"},"PeriodicalIF":2.1,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13714357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strengthening Blood Transfusion Safety in Somalia: Challenges, Opportunities, and the Need for a Sustainable National Blood System. 加强索马里输血安全:挑战、机遇和建立可持续国家血液系统的必要性。
IF 2.1
Journal of Blood Medicine Pub Date : 2026-10-21 eCollection Date: 2026-01-01 DOI: 10.2147/JBM.S651422
Abdikani Omar Salah
{"title":"Strengthening Blood Transfusion Safety in Somalia: Challenges, Opportunities, and the Need for a Sustainable National Blood System.","authors":"Abdikani Omar Salah","doi":"10.2147/JBM.S651422","DOIUrl":"10.2147/JBM.S651422","url":null,"abstract":"<p><p>Blood transfusion is essential for obstetric, trauma, surgical, and chronic care, yet the organization of transfusion services in Somalia is poorly documented. This narrative commentary summarizes published hospital-based studies of blood donors in Somalia and Somaliland and discusses implications for a coordinated national blood service. Targeted searches identified four donor studies (three in Mogadishu and one in Hargeisa; 165,196 donor records in total) and one blood group study, which were read together with World Health Organization and United Nations documents. The studies were hospital-based, differed in design, period, assays, and donor definitions, and are not nationally representative. Donors were almost entirely male (93.9% to 99.8%). Donor type differed by site: 80.8% of donors at one hospital were family donors, donors at another were described as mostly paid, and 61.9% of donors in a smaller study were voluntary. Hepatitis B positivity ranged from 0.6% to 9.7% across these study populations, with different case definitions; these are study-specific figures, not national prevalence estimates. At one hospital, overall transfusion-transmitted infection (TTI) positivity declined from 4.27% in 2016 to 1.98% in 2022, a temporal association whose cause was not established. We describe challenges in donor recruitment, screening quality, regulation, hemovigilance, and financing, and propose recommendations ordered by dependency, feasibility, and supporting evidence, with indicators for monitoring. A coordinated national blood service is presented as an implication of this evidence that requires nationally representative surveillance to evaluate.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"17 ","pages":"651422"},"PeriodicalIF":2.1,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13696848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149267867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of HPA Genotypes w ith Platelet Apheresis Donation Frequency and Yield Among Chinese Donors: A Cross-Sectional Study. 中国献血者HPA基因型与血小板单采捐献频率和产量的相关性:一项横断面研究。
IF 2.1
Journal of Blood Medicine Pub Date : 2026-10-14 eCollection Date: 2026-01-01 DOI: 10.2147/JBM.S637147
Weiwei Fang, Fengliang Lu, Xin Li, Meng Wang, Xiying Li
{"title":"Association of HPA Genotypes w ith Platelet Apheresis Donation Frequency and Yield Among Chinese Donors: A Cross-Sectional Study.","authors":"Weiwei Fang, Fengliang Lu, Xin Li, Meng Wang, Xiying Li","doi":"10.2147/JBM.S637147","DOIUrl":"10.2147/JBM.S637147","url":null,"abstract":"<p><strong>Background: </strong>Human platelet antigens (HPA) are clinically significant in transfusion refractoriness, but whether HPA genotypes are associated with cumulative donation frequency or apheresis yield remains unknown.</p><p><strong>Methods: </strong>We genotyped 1,242 platelet apheresis donors from Harbin, China for eight HPA systems (HPA-1, -2, -3, -4, -5, -6, -15, and -21). Outcomes were cumulative donation count and index yield (0.5/1/2 units). Univariate analyses used Kruskal-Wallis and Mann-Whitney tests. Multivariable negative binomial and binary logistic regressions adjusted for age, sex, ABO, and ethnicity. Sensitivity analyses excluded first-time donors, stratified by age, and removed the top 5% of donors.</p><p><strong>Results: </strong>HPA-3 and HPA-15 were the most polymorphic (b-allele frequencies: 42.0% and 44.5%). However, neither HPA-3 nor HPA-15 was significantly associated with cumulative donation count in multivariable negative binomial regression (HPA-15 ab vs aa+bb: IRR=1.02, 95% CI: 0.90-1.15, P=0.79; HPA-3 b carrier vs aa: IRR=0.97, 95% CI: 0.85-1.10, P=0.66). Similarly, no significant association was found between HPA-15 b carrier status and apheresis yield (OR=0.97, 95% CI: 0.76-1.25, P=0.83). These null findings remained consistent across all sensitivity analyses.</p><p><strong>Conclusion: </strong>In this cohort of northern Chinese Han platelet apheresis donors, HPA genotypes-including the polymorphic HPA-3 and HPA-15 systems-were not significantly associated with donation frequency or apheresis yield.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"17 ","pages":"637147"},"PeriodicalIF":2.1,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatitis A-Associated Very Severe Aplastic Anemia in a Young Adult Female: A Case Report. 1例年轻成年女性甲型肝炎相关的极重度再生障碍性贫血。
IF 2.1
Journal of Blood Medicine Pub Date : 2026-10-10 eCollection Date: 2026-01-01 DOI: 10.2147/JBM.S624005
Taher A Alhaddad, Ahmed Alsaffar, Bashair Alnemer, Lojain Alsahman Ii, Reda Aleid, Shahab Ahmed Alsuliman Snr
{"title":"Hepatitis A-Associated Very Severe Aplastic Anemia in a Young Adult Female: A Case Report.","authors":"Taher A Alhaddad, Ahmed Alsaffar, Bashair Alnemer, Lojain Alsahman Ii, Reda Aleid, Shahab Ahmed Alsuliman Snr","doi":"10.2147/JBM.S624005","DOIUrl":"https://doi.org/10.2147/JBM.S624005","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis‑associated aplastic anemia (HAAA) is a rare but life‑threatening immune‑mediated complication of acute viral hepatitis, and hepatitis A virus is an uncommon cause of this syndrome.</p><p><strong>Case presentation: </strong>We report the case of a 24‑year‑old woman who developed acute hepatitis A followed by rapidly progressive pancytopenia fulfilling the criteria for very severe aplastic anemia. Her clinical course was complicated by febrile neutropenia, transfusion dependence, gastrointestinal bleeding, and <i>Stenotrophomonas maltophilia</i> bacteremia. Bone marrow biopsy demonstrated marked hypocellularity with severe trilineage suppression. Despite intensive supportive care including broad-spectrum antimicrobial therapy and transfusion support, her clinical condition deteriorated, and she died from infectious and hemorrhagic complications before definitive therapy could be initiated. This case emphasizes the importance of early recognition of cytopenias during the acute phase of hepatitis and prompt hematology referral for definitive management.</p><p><strong>Conclusion: </strong>Aplastic anemia following acute hepatitis A infection is rare but potentially fatal. Early recognition of cytopenias during or following acute hepatitis, prompt bone marrow evaluation, and urgent hematology referral is essential for timely definitive treatment and improved outcomes.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"17 ","pages":"624005"},"PeriodicalIF":2.1,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13664683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149192867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Outcomes of Generic and Branded Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Single-Center Within-Patient Analysis. 比较通用的结果和品牌达沙替尼在慢性粒细胞白血病慢性期患者:一个单中心Within-Patient分析。
IF 2.1
Journal of Blood Medicine Pub Date : 2026-10-05 eCollection Date: 2026-01-01 DOI: 10.2147/JBM.S625380
Anas Babiker, Elrazi A Ali, Alaa Rahhal, Rola Ghasoub, Amir Mohamed Nounou, Anas Hamad, Mohamed A Yassin
{"title":"Comparative Outcomes of Generic and Branded Dasatinib in Chronic-Phase Chronic Myeloid Leukemia: A Single-Center Within-Patient Analysis.","authors":"Anas Babiker, Elrazi A Ali, Alaa Rahhal, Rola Ghasoub, Amir Mohamed Nounou, Anas Hamad, Mohamed A Yassin","doi":"10.2147/JBM.S625380","DOIUrl":"https://doi.org/10.2147/JBM.S625380","url":null,"abstract":"<p><strong>Background: </strong>Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukaemia (CML) from a fatal malignancy into a manageable chronic condition. Second-generation TKIs, including dasatinib, achieve faster, deeper molecular responses and overcome imatinib resistance or intolerance. However, high acquisition costs limit access, particularly in resource-constrained settings. The FDA approval of generic dasatinib in September 2024 represents a landmark step towards affordability.</p><p><strong>Methods: </strong>A retrospective, single-center, within-patient paired cohort study, paired before-after design was conducted at the National Center for Cancer Care and Research in Qatar. A 58 adults patients with confirmed chronic-phase CML (CP-CML) who transitioned from branded Sprycel<sup>®</sup>(dasatinib) to Daleubin<sup>®</sup> (dasatinib) between January 2024 and December 2025 were included. Primary outcomes were hematologic and major molecular response rates. Secondary outcomes included adverse events, adherence, dose modifications, and toxicity-related hospitalizations. Paired t-tests and McNemar's exact test were applied. .</p><p><strong>Results: </strong>Fifty-eight patients were included (mean follow-up 6 months). Complete hematologic response was achieved (maintained) in all patients (100%); major molecular response in 56 (96.6%). No grade 3-4 adverse events occurred. Overall adverse-event rates were comparable between formulations (15.5% vs 13.8%; P = 1.000). During the follow-up period, toxicity-related hospitalizations were numerically lower with generic dasatinib but not statistically significant (1.7% vs 10.3%; P = 0.063). A statistically significant but clinically modest platelet count increase was observed post-switch (211.5 ± 64.9 vs 233.8 ± 95.4×10<sup>9</sup>/L; P = 0.046). .</p><p><strong>Conclusion: </strong>Despite the primary limitation of a small sample size and short follow up period, generic dasatinib formulation, demonstrated short-term safety and efficacy comparable to those of the branded formulation. High response rates, favorable tolerability, and fewer hospitalizations were observed, supporting its potential as a more cost-accessible treatment option. However, these findings should be interpreted cautiously, and larger, multicenter prospective studies with longer follow-up are needed to confirm comparative effectiveness, safety, and long-term clinical outcomes.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"17 ","pages":"625380"},"PeriodicalIF":2.1,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13651728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书